Out now! #APCCC26 @APCCC_Lugano @AOmlin @Silke_Gillessen
Treatment Effect of Perioperative (Neoadjuvant and Adjuvant) Apalutamide #LAPC #ProstateCancer #Proteus sciencedirect.com/science/articl…

Excited to share ManUSPECTRAL in @BJUIjournal 🔬

1,095 hyperspectral recordings from 159 urological procedures across 17 organ classes as a foundation for future image-guided tissue identification in surgery.

📖 bjui-journals.onlinelibrary.wiley.com/doi/10.1111/bj…

Published in @EurUrolFocus: our prospective PAUSE-URO study (n=480) on perioperative DOAC management in urological surgery — interruption 2–4d, reduced-dose POD1 resumption, no heparin bridging. Bleeding: 4.3% (vs. 8% threshold).

📖 doi.org/10.1016/j.euf.…

🚨 PARP-i in metastatic hormone-sensitive #ProstateCancer🚨

📜#TALAPRO3 out in @NEJM

In HRR-altered mHSPC, adding talazoparib to enzalutamide + ADT:

✅ Reduced risk of progression/death by 52% (HR 0.48)
📈 3-year rPFS: 77% vs 56%
⏳ OS trend favors combination (HR 0.77), but a (Grade ≥3: 51%).

👉Potential new standard for a biomarker-selected population

@neerajaiims @urotoday @renalandurology @UrologyTimes @UroOnc @SUO_YUO @PCFnews

🔗shorturl.at/2PBvi

Among cisplatin-eligible patients with muscle-invasive bladder cancer undergoing cystectomy, perioperative enfortumab vedotin–pembrolizumab led to significantly better event-free survival outcomes than cisplatin–gemcitabine. Full phase 3 KEYNOTE-B15/EV-304 trial results: nej.md/4wh8FB9

Editorial: A New Standard in Muscle-Invasive Bladder Cancer — The End of the Cisplatin Era? nej.md/4b67lZi

#YAU_RenalCancerSpotlight No. 11

📌Lessons from ROBOCOPII & OpeRa — open vs robot-assisted PN. Both safe & equivalent, but we need better, patient-centred trial endpoints

📖 @MUN_journal
pubmed.ncbi.nlm.nih.gov/42318694/

✍️@PandolfoSD @wuzhenjie17 @danieleamparore @Ric_Campi

Couldn't agree more! - As robotic surgeons, we should support surgical AI — but not at the cost of losing control over the data generated by our patients and our work!

Perioperative durvalumab (12 months) with neoadjuvant EV (3 cycles) shows ‘statistically significant and clinically meaningful’ improved EFS and OS vs cystectomy alone in MIBC (like KN905 (EVP cs cystectomy)). The shorter period of EV is the major difference in trial designs. toxicity will be important. The 3rd arm, where tremelimumab was added as a triplet, did not hit OS at this stage. astrazeneca.com/media-centre/p… @OncoAlert

@AmerUrological Proud moment to have not only one, but two of our papers featured in the AUA Daily Scope.

One on DeepTRUS and AI-assisted prostate cancer diagnosis using transrectal microultrasound, and one on neoadjuvant treatment strategies in muscle-invasive bladder cancer.

ASCO abstracts just released:

Super exciting to see that the phase 3 PROTEUS trial will finally being presented in the #ASCO2026 plenary!

Perioperative apalutamide + ADT in high-risk localized/locally advanced prostate cancer could mark a true paradigm shift in this space. 🚀

@urotoday @OncoAlert @JNJNews @weoncologists @DrChoueiri @Markuseckstein3 @ProfHadaschik @ViktorGruenwald @imedverse @ASCO @ASCOPost

What is EVIglance?

Now live: the Evidence Map of Bladder Cancer Surgery by @VLSWieland and Karl Kowalewski from Urology Mannheim. A total of 129 RCTs with 14,645 patients.
Explore it here: map.eviglance.com
#BladderCancer #Urology #EvidenceBasedMedicine

📢Final call from the @EAU_YAUroTech group!

We’re mapping the #AI maturity of urologic centers — and we need your input!

👫Open to all urologists
⏰ Only 8 minutes to complete

Help shape the future of AI in urology 👇 surveymonkey.com/r/RR93FTP

The TALAPRO-3 study met its primary endpoint. Overall survival data are still immature and not yet statistically significant. We will have to wait and see how much benefit is observed in the HRR and non-HRR subgroups, but this is great news!!

🤖 How ready is your urology department for AI?

We’re mapping the AI maturity of urologic centers worldwide — and we need your input.

👨‍⚕️ Open to all urologists
⏱ Takes only 8 minutes

Help shape the future of AI in urology 👇
🔗 surveymonkey.com/r/RR93FTP

@EAUYAUrology @Uroweb

Scientists at the DKFZ and @uniklinik_hd are presenting a method known as “xeno-learning" that enables artificial intelligence (AI) to learn how to transfer medical image data from animals to humans. @lena_maierhein @natBME
t1p.de/8jzg3

🚨 Our 2-year results from the randomized ROBOCOP II trial are out. RAPN vs OPN for localized RCC:

📖sciencedirect.com/science/articl…

@KFKowalewski @HaneyCaelan @MaximilianKriegmair @UMM_Urology

🚀 New in Nature Biomedical Engineering: "Xeno-learning: transferring knowledge across species for hyperspectral imaging"

📄doi.org/10.1038/s41551…

Jan Sellner, @AlexanderStuFi, @lena_maierhein, @doctor_felix, @KFKowalewski, @DKFZ

MUST READ for urologist and radonc!

Real world data on late GU toxicity after radiotherapy for prostate cancer

Short term is underestimation of the real burden for the patient. Important when counselling patients for decision making.

@aleantonellibs1 @RicBertolo

🚨23 years of PSA screening in @NEJM 🚨

👉ERSPC RCT of >162k patients

📅Median 23 year f/u PSA screening lead to...

📉 #prostatecancer mortality by 13%

✅1 death prevented for every 456 men invited for screening or 12 diagnosed w/ PCa

📉Risk of advanced PCa by 34%

⭐️Benefit cone as harm-benefit ratio improves

🔗shorturl.at/ajgNN

@PCF_Science @PCFnews @urotoday @UrologyTimes @renalandurology @UroOnc